All News
English for the Biologically-Challenged (8.4.2023)
Dr. Jack Cush reviews the news and journal articles from the past week on RheumNow.com. This week highlights Veterans, Vegetarians and Antenatal Corticosteroids.
Read ArticleRheumatology Journals Rife With Faulty Conflict-of-Interest
More often than not, conflict-of-interest disclosures in three major rheumatology journals didn't match records in the U.S. government's Open Payments database, researchers found.
Read Article2023-2024 Best Rheumatology Hospitals
Johns Hopkins Hospital in Baltimore has been named the top hospital for rheumatology by U.S. News & World Report. This is the 6th year in a row they have held this spot.
Read ArticleUnrecognized Mental Health Problems in Autoimmune Diseases
More than half of patients with auto-immune conditions experience mental health conditions such as depression or anxiety, yet the majority are rarely or never asked in clinic about mental health symptoms, according to new research from the University of Cambridge and King’s College London.
Read ArticleMMWR: Arthritis Among Children and Adolescents
The CDC estimates that nearly 220,000 children and adolescents had arthritis during 2017–2021.
Read ArticleDanger with Hydroxychloroquine Nonadherence in SLE
A large cohort study shows that severe non-adherence to hydroxychloroquine (HCQ) results in serious risks for SLE flares, damage, and mortality.
Read ArticleLinks:
EULAR Points to Consider in Progressing Psoriasis to Psoriatic Arthritis
The transition from psoriasis to PsA – and the early diagnosis of PsA – is of considerable scientific and clinical interest. People typically have psoriatic skin disease for a decade or more before they begin to experience the joint involvement of PsA.
Read ArticleICYMI: ChatGPT - A Boon or Threat to Scientific Publication?
ChatGPT is a new, artificial intelligence chatbot that has dramatically changed the digital worlds of education, research, graphic design, statistics and more. While this AI driven platform has the untold potential in generating written content, there is considerable concern in assuring that human-generated content of research, education and publishing has veracity.
Read ArticleICYMI: GRAPPA Recommendations for Treating Enthesitis in Psoriatic Arthritis
GRAPPA has provided new, evidence based updates to the management of enthesitis in patients with psoriatic arthritis (PsA), affecting at least 30% of PsA patients and is associated with more severe disease, x-ray damage, and poorer outcomes.
Read ArticleICYMI: Carpal Tunnel - Steroid injection vs. Night Splinting
A prospective, pragmatic, open-label, randomized trial conducted by the UK National Health Service, studied interventions in patients with carpal tunnel syndrome (CTS) and found no advantage to either CTS corticosteroid injection (CSI) or night splinting (NS) as the initial treatment of CTS.
Read ArticleFDA Delays Bimekizumab Decision, Again
Editor's Note: please note the error in the original report has been corrected to read: UCB affirms there are no open information requests from the FDA regarding the BLA for bimekizumab or bimekizumab manufacturing.
Read ArticleWhy Patients Don't Take Medicines
About 60% of adults aged 18 and over reported taking at least one prescription medication in 2021, with 36% reporting taking three or more. Out-of-pocket costs on retail drugs rose 4.8% to $63 billion in 2021.
Read ArticleAre bDMARDs, tsDMARDs and biosimilar DMARDs cost effective?
Treatment advances with new biologic disease-modifying antirheumatic drugs (bDMARDs), targeted synthetic DMARDs (tsDMARDs) and biosimilar DMARDs (bsDMARDs) have proven efficacy and safety; but does their increased cost yield commensurate benefits in patients with rheumatoid arthritis (RA) and high disease activity?
Read ArticleAbatacept Safety Outcomes Across 7 European Registries
A multinational registry analysis of rheumatoid arthritis (RA) receiving abatacept (ABA) has shown that the safety profile of ABA remains unchanged with no new or increased risks of infection or malignancy.
Read Article2023 EULAR Recommendations on Imaging in Crystal-Induced Arthritis
New recommendations on imaging for crystal-induced (gout, CPPD) arthritis (CiA) were presented at EULAR 2023 in Milan.
Read ArticleACR Concerned with MedPAC’s Cutting Part B Reimbursement
The American College of Rheumatology (ACR) today expressed disappointment that the Medicare Payment Advisory Commission (MedPAC) has recommended yet another cut to physician reimbursement for infusing life-altering treatments as part of its June 2023 Report to the Congress: Medicare and the Healt
Read ArticleWhy Depression Screening Should be Mandatory at Each Visit
Depression is more widespread than ever in the United States, according to a new study from Gallup, showing that 18% of adults are depressed (or receiving depression treatment for depression) – an increase in 7 percentage points since 2015.
Read ArticleHigh Mortality Rates with Depression in Rheumatoid Arthritis
A Danish cohort study has shown a deadly association between depression and rheumatoid arthritis (RA).
Read ArticleBiosimilars Match Biologic Originators in Rheumatoid Arthritis
A systematic review and meta-analysis in JAMA Network Open has shown that biosimilars of adalimumab, infliximab, and etanercept were associated with clinically equivalent treatment effects compared with their reference biologics for the treatment of rheumatoid arthritis (RA).
Read Article